UT Health Science Center-San Antonio: Mays Cancer Center Researcher and SignalRx Earn NCI Business Grants to Develop Drugs for First-In-Human Clinical Trials
March 11, 2022
March 11, 2022
SAN ANTONIO, Texas, March 11 (TNSRes) -- The University of Texas Health Science Center at San Antonio issued the following news release:
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials.
The clinical translational researcher, Daruka Mahadevan . . .
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials.
The clinical translational researcher, Daruka Mahadevan . . .